
    
      This study is an open label, randomized, two-treatment, two-period, two-sequence,
      single-center, crossover study comparing the pharmacokinetics, safety and tolerability of
      MNS075 (intranasal morphine) at doses of 7.5 mg self-administered q1h for 7 hours (8 doses)
      and 15 mg self-administered q3h for 9 hours (4 doses).
    
  